Original Abstracts & Papers

  1. Kalappa,B.I., Heun, S., Duignan, K.M., Furuya, T., Edwards, D.S., Anastasios V. Tzingounis, A.V., and Tzounopoulos, T. Potent KCNQ2/3-Specific Channel Activator Suppresses In Vivo Epileptic Activity and Prevents the Development of Tinnitus. Journal of Neuroscience (2015).
  2. Heidebrecht, R., Edwards, D.S., Duggan, M. & Askew, B.C. Fluorination shifts the profile of an endogenous neurotransmitter. Gordon Research Conference on Medicinal Chemistry (2013).
  3. Furuya, T., Edwards, D.S., Duggan, M., & Askew, B.C. Novel KCNQ2/3 channel opener with improved potency and channel selectivity as a potential new treatment for partial-onset seizures: pre-clinical characterization. Int'l Epilepsy Congress (2013).
  4. Purohit, A., Furuya, T. & Edwards, D.S. Synthesis of [18F]-aryl fluoride tracers using Pd(IV)-based electrophilic fluorination: critical design considerations. Society of Nuclear Medicine and Molecular Imaging (2013).
  5. Furuya, T., Edwards, D.S. & Duggan, M. Utilizing the transformational power of fluorine to optimize a health authority-approved KCNQ2/3 potassium channel opener. Gordon Research Conference on Medicinal Chemistry (2012).
  6. Furuya, T. & Ritter, T. Fluorination of boronic acids mediated by silver(I) triflate. Org. Lett. 11, 2860-2863 (2009).
  7. Furuya, T. & Ritter, T. Carbon−fluorine reductive elimination from a high-valent palladium fluoride. J. Am. Chem. Soc. 130, 10060-10061 (2008).
  8. Furuya, T., Kaiser, H.M. & Ritter, T. Palladium-mediated fluorination of arylboronic acids. Angew. Chem. Int. Ed. 47, 5993-5996 (2008).


SciFluor News

SciFluor Announces Positive Top-Line Results of Phase 1/2 Study of SF0166 Eye Drops to Treat Wet Age-Related Macular Degeneration
read more >

SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases
read more >

SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients
read more >